John R Bergquist1,2, Tommy Ivanics1,2, Christopher R Shubert1,2, Elizabeth B Habermann2, Rory L Smoot1, Michael L Kendrick1, David M Nagorney1, Michael B Farnell1, Mark J Truty3. 1. Division of Hepatobiliary Surgery, Section of Subspecialty General Surgery, Department of Surgery, Mayo Clinic, Rochester, MN, USA. 2. Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, MN, USA. 3. Division of Hepatobiliary Surgery, Section of Subspecialty General Surgery, Department of Surgery, Mayo Clinic, Rochester, MN, USA. truty.mark@mayo.edu.
Abstract
INTRODUCTION: Adjuvant chemotherapy improves survival after curative intent resection for localized pancreatic adenocarcinoma (PDAC). Given the differences in perioperative morbidity, we hypothesized that patients undergoing distal partial pancreatectomy (DPP) would receive adjuvant therapy more often those undergoing pancreatoduodenectomy (PD). METHODS: The National Cancer Data Base (2004-2012) identified patients with localized PDAC undergoing DPP and PD, excluding neoadjuvant cases, and factors associated with receipt of adjuvant therapy were identified. Overall survival (OS) was analyzed using multivariable Cox proportional hazards regression. RESULTS: Overall, 13,501 patients were included (DPP, n = 1933; PD, n = 11,568). Prognostic characteristics were similar, except DPP patients had fewer N1 lesions, less often positive margins, more minimally invasive resections, and shorter hospital stay. The proportion of patients not receiving adjuvant chemotherapy was equivalent (DPP 33.7%, PD 32.0%; p = 0.148). The type of procedure was not independently associated with adjuvant chemotherapy (hazard ratio 0.96, 95% confidence interval 0.90-1.02; p = 0.150), and patients receiving adjuvant chemotherapy had improved unadjusted and adjusted OS compared with surgery alone. The type of resection did not predict adjusted mortality (p = 0.870). CONCLUSION: Receipt of adjuvant chemotherapy did not vary by type of resection but improved survival independent of procedure performed. Factors other than type of resection appear to be driving the nationwide rates of post-resection adjuvant chemotherapy in localized PDAC.
INTRODUCTION: Adjuvant chemotherapy improves survival after curative intent resection for localized pancreatic adenocarcinoma (PDAC). Given the differences in perioperative morbidity, we hypothesized that patients undergoing distal partial pancreatectomy (DPP) would receive adjuvant therapy more often those undergoing pancreatoduodenectomy (PD). METHODS: The National Cancer Data Base (2004-2012) identified patients with localized PDAC undergoing DPP and PD, excluding neoadjuvant cases, and factors associated with receipt of adjuvant therapy were identified. Overall survival (OS) was analyzed using multivariable Cox proportional hazards regression. RESULTS: Overall, 13,501 patients were included (DPP, n = 1933; PD, n = 11,568). Prognostic characteristics were similar, except DPPpatients had fewer N1 lesions, less often positive margins, more minimally invasive resections, and shorter hospital stay. The proportion of patients not receiving adjuvant chemotherapy was equivalent (DPP 33.7%, PD 32.0%; p = 0.148). The type of procedure was not independently associated with adjuvant chemotherapy (hazard ratio 0.96, 95% confidence interval 0.90-1.02; p = 0.150), and patients receiving adjuvant chemotherapy had improved unadjusted and adjusted OS compared with surgery alone. The type of resection did not predict adjusted mortality (p = 0.870). CONCLUSION: Receipt of adjuvant chemotherapy did not vary by type of resection but improved survival independent of procedure performed. Factors other than type of resection appear to be driving the nationwide rates of post-resection adjuvant chemotherapy in localized PDAC.
Authors: Alice C Wei; Fang-Shu Ou; Qian Shi; Xiomara Carrero; Eileen M O'Reilly; Jeffrey Meyerhardt; Robert A Wolff; Hedy L Kindler; Douglas B Evans; Vikram Deshpande; Joseph Misdraji; Eric Tamm; Dushyant Sahani; Malcolm Moore; Elliot Newman; Nipun Merchant; Jordan Berlin; Laura W Goff; Peter Pisters; Mitchell C Posner Journal: Ann Surg Oncol Date: 2019-08-15 Impact factor: 5.344
Authors: Nadia N Khan; Tennille Lewin; Amy Hatton; Charles Pilgrim; Liane Ioannou; Luc Te Marvelde; John Zalcberg; Sue Evans Journal: Am J Cancer Res Date: 2022-02-15 Impact factor: 6.166
Authors: Calvin L Cole; Christopher A Beck; Deja Robinson; Jian Ye; Bradley Mills; Scott A Gerber; Edward M Schwarz; David Linehan Journal: PLoS One Date: 2020-06-19 Impact factor: 3.240
Authors: Feng Yin; Mohammed Saad; Jingmei Lin; Christopher R Jackson; Bing Ren; Cynthia Lawson; Dipti M Karamchandani; Belen Quereda Bernabeu; Wei Jiang; Teena Dhir; Richard Zheng; Christopher W Schultz; Dongwei Zhang; Courtney L Thomas; Xuchen Zhang; Jinping Lai; Michael Schild; Xuefeng Zhang; Hao Xie; Xiuli Liu Journal: Gastroenterol Rep (Oxf) Date: 2020-11-24
Authors: John R Bergquist; Cornelius A Thiels; Christopher R Shubert; Tommy Ivanics; Elizabeth B Habermann; Santhi S Vege; Travis E Grotz; Sean P Cleary; Rory L Smoot; Michael L Kendrick; David M Nagorney; Mark J Truty Journal: Cancer Med Date: 2021-07-21 Impact factor: 4.452